CONFIDOSE IM AUTO-INJECTOR

K060389 · Pharma-Pen, Inc. · KZH · Jun 6, 2006 · General Hospital

Device Facts

Record IDK060389
Device NameCONFIDOSE IM AUTO-INJECTOR
ApplicantPharma-Pen, Inc.
Product CodeKZH · General Hospital
Decision DateJun 6, 2006
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 880.6920
Device ClassClass 2
AttributesTherapeutic

Intended Use

The ConfiDose™ IM auto-injector is a semi-automatic injection system intended to be used for the manual transfer, containment and intramuscular injection of liquid drugs and biologics under the direction of a physician. The ComfiDose™ IM auto-injector system includes an automatic needle retraction mechanism that is intended to aid in the prevention of accidental needle sticks. The ConfiDose™ IM auto-injector system is intended to mask needle insertion, injection and needle withdrawal from patient view.

Device Story

ConfiDose™ IM auto-injector is a semi-automatic, single-use, ETO-sterilized system for intramuscular delivery of liquid drugs and biologics. Device consists of a syringe cartridge with prefixed needle, power pack housing, and window tube. Operation is pressure-actuated; spring-loaded mechanism inserts needle to predetermined depth, dispenses medication, and automatically retracts needle to prevent accidental sticks. Device masks needle insertion, injection, and withdrawal from patient view. Used in clinical settings under physician direction. Benefits include standardized injection depth, automated delivery, and enhanced safety via needle retraction.

Clinical Evidence

Bench testing only. Performance assessed per ISO 11608-1:2000. Metrics included dose accuracy, dead space, flow rate, injection/dwell time, reliability, penetration depth accuracy, needle bond strength, leakage, non-coring properties, penetration force, actuation force, torque, syringe marking accuracy, chemical resistance, free fall resistance, and environmental stability. Device met all specifications.

Technological Characteristics

Spring-loaded, pressure-actuated auto-injector. Materials: syringe cartridge, needle, power pack housing, window tube. Sterilization: ETO. Single-use. Complies with ISO 11608-1. Mechanical operation; no electronic or software components.

Indications for Use

Indicated for patients requiring intramuscular injection of liquid drugs and biologics; intended for use under physician direction.

Regulatory Classification

Identification

A syringe needle introducer is a device that uses a spring-loaded mechanism to drive a hypodermic needle into a patient to a predetermined depth below the skin surface.

Predicate Devices

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ K0600389 1 of 2 ## 510(k) SUMMARY ConfiDose™ IM Auto-injector # Submitter's Name, Address, Telephone Number, Contact Person and Date Prepared: Pharma-Pen, Inc. 6136 FM 1616 Athens, TX 75752 Phone: (903) 677-5017 Facsimile: (903) 677-6083 JUN - 6 2006 Contact Person: Richard D. Gillespie III, P.E. Date Prepared: February 6, 2006 ## Name of Device and Name/Address of Sponsor: | Trade Name:<br>Name / Address of sponsor: | Confi <i>Dose</i> ™ IM Auto-injector<br>Pharma-Pen, Inc.<br>6136 FM 1616<br>Athens, TX 75752<br>Phone: 1-903-677-5017<br>Facsimile: 1-903-677-6083 | |-------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | Common or Usual Name: | Auto Injector | | Classification Name: | Introducer, Syringe Needle<br>Regulation Number: 880.6920<br>Medical Specialty: General Hospital<br>Product Code: KZH<br>Device Class: Class II | | Predicate Devices: | • Union Medico Aps.; Personal Injector (K033696),<br>• Biogen; Invisiject™ Reusable Auto Injector (K032425),<br>• Pharma-Pen Inc.; Confi <i>Dose</i> Auto-Injector (K042557). | #### Intended Use: The ConfiDose™ IM auto-injector is a semi-automatic injection system intended to be used for the manual transfer, containment and intramuscular injection of liquid drugs and biologics under the direction of a physician. The ComfiDose™ IM auto-injector system includes an automatic needle retraction mechanism that is intended to aid in the prevention of accidental needle sticks. The ConfiDose™ IM auto-injector system is intended to mask needle insertion, injection and needle withdrawal from patient view. > Attachment J Page 1 of 2 {1}------------------------------------------------ ### Technological Characteristics and Substantial Equivalence: The ConfiDose™ IM auto-injector consists of a syringe cartridge with prefixed needle, power pack housing with spring loaded mechanism to insert a hypodermic needle into a patient to predetermined depth below the skin surface and a window tube with springloaded retraction mechanism. It is pressure actuated. Once activated, the device automatically performs all three steps of the injection process, needle insertion, drug injection and needle withdrawal. The ConfiDose™ IM auto-injector is individually packaged and ETO sterilized for single use. The ConfiDose™ IM auto-injector utilizes a spring-loaded mechanism to insert a hypodermic needle into a patient to predetermined depth below the skin surface and dispense the medication, and includes an automatic spring-loaded retraction mechanism. The same technological characteristics are found in various commercially marketed autoinjectors, which operate on the generally same principle. In contrast to ConfiDose™ IM auto-injector, the predicate devices (except the ConfiDose auto-injector K042557) do not automatically retract the hypodermic needle after the injection process is completed. The ConfiDose™ IM auto-injector is substantially equivalent to the other currently marketed auto-injectors, which are referenced above. The ConfiDose™ IM auto-injector and its predicate devices are all Introducer, Syringe Needle products. As described in the substantial equivalency table and supported by the extensive testing performed by the company, the ConfiDose™ IM auto-injector raises no new issues of safety or effectiveness. #### Performance Data: FDA has established no performance standards for this device classification. Performance of the ConfiDose™ IM auto-injector was assessed using applicable sections and methods specified in ISO 11608-1: Pen-Injectors for Medical Use-Part 1: Requirements and Test Method. Dose accuracy, dead space, flow rate, injection time / dwell time, reliability (number of activations without failure), accuracy of penetration depth, needle bond strength, absence of leakage, verification of non-coring needle properties, needle penetration force, device actuation force, torque necessary to defeat the safety of the device, verification of syringe markings accuracy, chemical resistance, free fall resistance, environmental stability were assessed. The device met all the requirements and specifications. In all instances, the ConfiDose™ IM auto-injector functioned as intended and the observed results were as expected. ### Conclusion Pharma-Pen, Inc. concludes, based on the information presented herein, that the ConfiDose™ IM auto-injector is substantially equivalent to similar products that have received FDA clearance and are currently legally marketed in the USA. {2}------------------------------------------------ Image /page/2/Picture/1 description: The image shows the logo for the Department of Health and Human Services (HHS). The logo consists of a stylized caduceus symbol, which features three abstract human figures connected by flowing lines, representing health and well-being. The text "DEPARTMENT OF HEALTH AND HUMAN SERVICES. USA" is arranged in a circular pattern around the symbol. JUN -6 2006 Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 Pharma-Pen, Incorporated C/O Mr. Jonathan S. Kahn, Esquire Hogan & Hartson, L.L.P. 555 Thirteenth Street Washington, D.C. 20004-1109 Re: K060389 Trade/Device Name: ConfiDose™ IM Auto-Injector Regulation Number: 880.6920 Regulation Name: Syringe Needle Introducer Regulatory Class: II Product Code: KZH Dated: May 16, 2006 Received: May 16, 2006 Dear Mr. Kahn: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. {3}------------------------------------------------ Page 2 - Mr. . Kahn Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html. Sincerely yours. Clues Chiu Lin, Ph.D. Director Division of Anesthesiology, General Hospital, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {4}------------------------------------------------ #### Indications for Use Statement 510(k) Number (if known):_____________________________________________________________________________________________________________________________________________________ Device Name: ConfiDose™ IM Auto-injector 1. 1. 1. 1. Indications for Use: The ConfiDose™ IM auto-injector is a semi-automatic injection system intended to be used for the manual transfer, containment and intramuscular injection of liquid drugs and biologics under the direction of a physician. The ConfiDose™ IM auto-injector system includes an automatic needle retraction mechanism that is intended to aid in the prevention of accidental needle sticks. The ConfiDose™ IM auto-injector system is intended to mask needle insertion, injection and needle withdrawal from patient view. Prescription Use _ V (Part 21 C.F.R. 801 Subpart D) AND/OR Over-The-Counter Use_ (21 C.F.R. 807 Subpart C) K06038 l of ## (PLEASE DO NOT WRITE BELOW THIS LINE -- CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) Shula A. Murphy, MD. Anthony Watson 6/1/04 Anas " Balogy General Hospital n Control, Lental Devic Number: K060389 ATTACHMENT L Page 1
Innolitics

Panel 1

/
Sort by
Ready

Predicate graph will load when search results are available.

Embedding visualization will load when search results are available.

PDF viewer will load when search results are available.

Loading panels...

Select an item from Submissions

Click any panel, subpart, regulation, product code, or device to see details here.

Section Matches

Results will appear here.

Product Code Matches

Results will appear here.

Special Control Matches

Results will appear here.

Loading collections...